Skip to content
value.today

Deva Holding A.S.: peers

Change the peers

Deva Holding A.S. beside the 7 companies most like it by industry, size and country: every figure with its date and source, its rank in the group and its percentile in its sector and country.

Deva Holding A.S., Kamada Ltd., EIS Eczacibasi Ilaç, Sinai Ve Finansal Yatirimlar Sanayi Ve Ticaret A.S., Pharmanutra S.p.A.: the market cap on file is more than 60 days old or a last known value (no market-data feed for their exchanges yet), so their valuation multiples and yields are shown but not ranked.

Side by side#

Every figure with its fiscal year or date and its source. Switch to each company's rank in the group, or its percentile in its sector or country. How ranks are worked out.

Deva Holding A.S., Kamada Ltd., EIS Eczacibasi Ilaç, Sinai Ve Finansal Yatirimlar Sanayi Ve Ticaret A.S., Aquestive Therapeutics, Inc., Evolus, Inc., Alpha Teknova, Inc., Ironwood Pharmaceuticals, Inc., Pharmanutra S.p.A. side by side: each figure with its period and source, its rank among these companies and its percentile in the company's sector and country
MeasureDeva Holding A.S.base
DEVA.IS · 🇹🇷 TR
Percentile in Healthcare
Percentile in Turkey
Kamada Ltd.
KMDA · 🇮🇱 IL
Percentile in Healthcare
Percentile in Israel
EIS Eczacibasi Ilaç, Sinai Ve Finansal Yatirimlar Sanayi Ve Ticaret A.S.
ECILC.IS · 🇹🇷 TR
Percentile in Healthcare
Percentile in Turkey
Aquestive Therapeutics, Inc.
AQST · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Evolus, Inc.
EOLS · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Alpha Teknova, Inc.
TKNO · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Ironwood Pharmaceuticals, Inc.
IRWD · 🇺🇸 US
Percentile in Healthcare
Percentile in USA
Pharmanutra S.p.A.
PHN.MI · 🇮🇹 IT
Percentile in Healthcare
Percentile in Italy
Group median
Size
Market cap (Better neither way: ranked highest first)$526 Mlast known, Jan 5, 2024 · Market dataLast known value: no current one4th of 8$463 MAug 1, 2026 · Market data8th of 8$1.1 BAug 1, 2026 · Market data1st of 8$508 MOct 30, 2026 · Market data5th of 8$501 MOct 16, 2026 · Market data6th of 8$494 MOct 29, 2026 · Market data7th of 8$599 MOct 30, 2026 · Market data2nd of 8$593 Mlast known, Jan 5, 2024 · Market dataLast known value: no current one3rd of 8$517 M8 ranked
Revenue (Better neither way: ranked highest first)——$180 MFY2025 · SEC3rd of 6——$45 MFY2025 · SEC5th of 6$297 MFY2025 · SEC1st of 6$41 MFY2025 · SEC6th of 6$296 MFY2025 · SEC2nd of 6$148 MFY2025 · ESEF4th of 6$164 M6 ranked
Net income (Higher is better)——$20 MFY2025 · SEC3rd of 6——$-84 MFY2025 · SEC6th of 6$-52 MFY2025 · SEC5th of 6$-17 MFY2025 · SEC4th of 6$24 MFY2025 · SEC1st of 6$23 MFY2025 · ESEF2nd of 6$1 M6 ranked
Employees (Better neither way: ranked highest first)——393December 31, 2025 · Profile1st of 5——147December 31, 2025 · Profile5th of 5334December 31, 2025 · Profile2nd of 5158December 31, 2025 · Profile4th of 5219As on 2021 · Profile3rd of 5——2195 ranked
Growth
Revenue growth (Higher is better)————+12.1%FY2025 · SEC2nd of 654th50th————-22.6%FY2025 · SEC6th of 610th5th+11.6%FY2025 · SEC3rd of 653rd65th+7.4%FY2025 · SEC4th of 643rd53rd-15.7%FY2025 · SEC5th of 612th7th+18.8%FY2025 · ESEF1st of 666th87th+9.5%6 ranked
Revenue growth, 3 years a year (Higher is better)————+11.7%FY2025 · SEC2nd of 558th55th————-2.3%FY2025 · SEC4th of 521st25th+26.0%FY2025 · SEC1st of 578th89th-0.7%FY2025 · SEC3rd of 525th30th-10.3%FY2025 · SEC5th of 512th10th————-0.7%5 ranked
Earnings per share growth (Higher is better)————+40.0%FY2025 · SEC1st of 273rd75th————————————————————+25.9%FY2025 · ESEF2nd of 268th70th+32.9%2 ranked
Margins and returns
Gross margin (Higher is better)————42.3%FY2025 · SEC3rd of 426th49th————58.3%FY2025 · SEC2nd of 450th72nd66.3%FY2025 · SEC1st of 462nd79th33.2%FY2025 · SEC4th of 419th40th————————50.3%4 ranked
Operating margin (Higher is better)————14.5%FY2025 · SEC3rd of 681st81st————-159.5%FY2025 · SEC6th of 617th7th-11.0%FY2025 · SEC4th of 647th26th-41.9%FY2025 · SEC5th of 634th16th33.3%FY2025 · SEC1st of 696th95th26.0%FY2025 · ESEF2nd of 693rd91st1.8%6 ranked
Net margin (Higher is better)————11.2%FY2025 · SEC2nd of 681st80th————-188.1%FY2025 · SEC6th of 616th6th-17.4%FY2025 · SEC4th of 644th23rd-42.6%FY2025 · SEC5th of 632nd16th8.1%FY2025 · SEC3rd of 675th70th15.2%FY2025 · ESEF1st of 686th85th-4.6%6 ranked
Free cash flow margin (Higher is better)————8.7%FY2025 · SEC2nd of 569th60th————-119.0%FY2025 · SEC5th of 519th7th-15.4%FY2025 · SEC3rd of 539th18th-24.2%FY2025 · SEC4th of 535th16th42.9%FY2025 · SEC1st of 598th99th————-15.4%5 ranked
Return on equity (Higher is better)————7.6%FY2025 · SEC2nd of 379th68th————————————-22.8%FY2025 · SEC3rd of 359th27th————30.4%FY2025 · ESEF1st of 395th92nd7.6%3 ranked
Valuation
P/E ratio (Better neither way: ranked highest first)————22.9×price Aug 1, 2026 · Market datanot ranked: old priceold priceold price————————————————4.0×price Oct 30, 2026 · Market dataonly one with it5th3rd————4.0×—
Price to sales (Better neither way: ranked highest first)————2.6×price Aug 1, 2026 · Market datanot ranked: old priceold priceold price————10.4×price Oct 30, 2026 · Market data2nd of 474th89th1.5×price Oct 16, 2026 · Market data3rd of 425th40th10.8×price Oct 29, 2026 · Market data1st of 475th90th1.5×price Oct 30, 2026 · Market data4th of 424th40th————6.0×4 ranked
Price to book (Better neither way: ranked highest first)————1.7×price Aug 1, 2026 · Market datanot ranked: old priceold priceold price————————————7.2×price Oct 29, 2026 · Market dataonly one with it77th84th————————7.2×—
Free cash flow yield (Higher is better)————3.4%price Aug 1, 2026 · Market datanot ranked: old priceold priceold price————-10.4%price Oct 30, 2026 · Market data4th of 442nd20th-9.1%price Oct 16, 2026 · Market data3rd of 444th22nd-2.0%price Oct 29, 2026 · Market data2nd of 462nd32nd21.2%price Oct 30, 2026 · Market data1st of 498th96th————-5.5%4 ranked
Financial strength
Debt to equity (Lower is better)————————————————————0.2×FY2025 · SEConly one with it31st22nd————————0.2×—
Piotroski F-score (Higher is better)——————2 of 9FY2025 · SEC2nd of 32 of 9FY2025 · SEC2nd of 35 of 9FY2025 · SEC1st of 3————2.0 of 93 ranked
Scorecard
Scorecard (Higher is better)——10 of 12FY2025 · Scorecard2nd of 6——2 of 20FY2025 · Scorecard6th of 68 of 19FY2025 · Scorecard4th of 66 of 21FY2025 · Scorecard5th of 611 of 20FY2025 · Scorecard3rd of 65 of 5FY2025 · Scorecard1st of 649% passed6 ranked
Valuation checks (Higher is better)——————0 of 5FY2025 · Scorecard3rd of 41 of 5FY2025 · Scorecard2nd of 40 of 5FY2025 · Scorecard3rd of 45 of 6FY2025 · Scorecard1st of 4——10% passed4 ranked
Growth checks (Higher is better)——6 of 6FY2025 · Scorecard1st of 6——0 of 6FY2025 · Scorecard6th of 65 of 6FY2025 · Scorecard3rd of 62 of 6FY2025 · Scorecard4th of 61 of 6FY2025 · Scorecard5th of 62 of 2FY2025 · Scorecard1st of 658% passed6 ranked
Profitability checks (Higher is better)——3 of 5FY2025 · Scorecard2nd of 6——0 of 4FY2025 · Scorecard6th of 61 of 4FY2025 · Scorecard4th of 61 of 5FY2025 · Scorecard5th of 62 of 4FY2025 · Scorecard3rd of 63 of 3FY2025 · Scorecard1st of 638% passed6 ranked
Financial health checks (Higher is better)——1 of 1FY2025 · Scorecard1st of 5——2 of 4FY2025 · Scorecard4th of 51 of 3FY2025 · Scorecard5th of 53 of 4FY2025 · Scorecard2nd of 52 of 3FY2025 · Scorecard3rd of 5——67% passed5 ranked
Shareholder returns checks (Higher is better)——————0 of 1FY2025 · Scorecard2nd of 40 of 1FY2025 · Scorecard2nd of 40 of 1FY2025 · Scorecard2nd of 41 of 1FY2025 · Scorecard1st of 4——0% passed4 ranked
Ownership
Held by institutions (Better neither way: ranked highest first)——8.9%2026-Q1 · 13F5th of 5——60.1%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in3rd of 576.6%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 516.7%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in4th of 592.8%2026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 5——60.1%5 ranked
Institutions holding (Better neither way: ranked highest first)——422026-Q1 · 13F5th of 5——1902026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in2nd of 51702026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in3rd of 51102026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in4th of 52322026-Q3 · 13FStill being filed: 98% of the filers of the quarter before are in1st of 5——1705 ranked
Institutional holding, change over the quarter (Better neither way: ranked highest first)——-0.4 pp2026-Q1 against 2025-Q4 · 13F4th of 5——-1.4 pp2026-Q2 against 2026-Q1 · 13F5th of 5+14.6 pp2026-Q2 against 2026-Q1 · 13F1st of 5+2.7 pp2026-Q2 against 2026-Q1 · 13F2nd of 5-0.2 pp2026-Q2 against 2026-Q1 · 13F3rd of 5——-0.2 pp5 ranked

Under each figure: its fiscal year, quarter or date, and its source. ↑ higher is better, ↓ lower is better, · better neither way (ranked highest first). Ranks count only the companies with the figure; percentiles place each company among all the companies of its own sector and country with the figure (ten or more needed).

† The market cap behind this figure is more than 60 days old (no market-data feed for that exchange yet): it is shown but not ranked or given a percentile.

Sources: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Editors = The company's annual report, entered by value.today editors; Wikidata = Wikidata, citing the annual report; Scorecard = value.today scorecard: thirty checks on the company's statements, worked out daily; 13F = SEC Form 13F holdings reports; SEC = Dividends declared per share in SEC 10-Q and 10-K filings; Profile = The company's latest reported headcount; Market data = Deva Holding A.S.: How market caps are worked out; Kamada Ltd.: How market caps are worked out; EIS Eczacibasi Ilaç, Sinai Ve Finansal Yatirimlar Sanayi Ve Ticaret A.S.: How market caps are worked out; Aquestive Therapeutics, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Evolus, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Alpha Teknova, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Ironwood Pharmaceuticals, Inc.: SEC closing prices (fails-to-deliver files) times the shares on the latest 10-K or 10-Q cover; Pharmanutra S.p.A.: How market caps are worked out.

Where each stands in its sector and country: Operating margin#

The dot is the company; the line runs from the 10th to the 90th percentile of all the companies of its sector (or country) with the figure, the box holds the middle half and the tick is the median. Each company's newest fiscal year; figures that divide by the market value only with a market cap at most 60 days old. How percentiles are worked out.

Operating margin: each company's figure and its percentile in its sector and its country
CompanyOperating marginIn its sectorIn its country
Deva Holding A.S.———
Kamada Ltd.14.5%FY2025
81st percentile in Healthcaremedian -7.7%, 674 companies
81st percentile in Israelmedian -0.2%, 67 companies
EIS Eczacibasi Ilaç, Sinai Ve Finansal Yatirimlar Sanayi Ve Ticaret A.S.———
Aquestive Therapeutics, Inc.-159.5%FY2025
17th percentile in Healthcaremedian -7.7%, 674 companies
7th percentile in USAmedian 3.5%, 2,594 companies
Evolus, Inc.-11.0%FY2025
47th percentile in Healthcaremedian -7.7%, 674 companies
26th percentile in USAmedian 3.5%, 2,594 companies
Alpha Teknova, Inc.-41.9%FY2025
34th percentile in Healthcaremedian -7.7%, 674 companies
16th percentile in USAmedian 3.5%, 2,594 companies
Ironwood Pharmaceuticals, Inc.33.3%FY2025
96th percentile in Healthcaremedian -7.7%, 674 companies
95th percentile in USAmedian 3.5%, 2,594 companies
Pharmanutra S.p.A.26.0%FY2025
93rd percentile in Healthcaremedian -7.7%, 674 companies
91st percentile in Italymedian 8.8%, 101 companies

Revenue by fiscal year, and the rank in the group#

Revenue of the fiscal year. US dollars at each year's exchange rate; fiscal years as each company names them. Ranks: 1st is the highest (better neither way).

Revenue

$0 M$111 M$221 M$332 M$443 M20102012201420162018202020222024Kamada Ltd. $180 MAquestive Therapeutics, Inc. $45 MEvolus, Inc. $297 MAlpha Teknova, Inc. $41 MIronwood Pharmaceuticals, Inc. $296 MPharmanutra S.p.A. $148 M

Rank in the group

1st2nd3rd4th5th6th20152016201720182019202020212022202320242025Kamada Ltd.: 2nd of 2 in 2015Kamada Ltd.: 2nd of 2 in 2016Kamada Ltd.: 2nd of 3 in 2017Kamada Ltd.: 2nd of 3 in 2018Kamada Ltd.: 2nd of 4 in 2019Kamada Ltd.: 2nd of 5 in 2020Kamada Ltd.: 2nd of 5 in 2021Kamada Ltd.: 3rd of 5 in 2022Kamada Ltd.: 3rd of 5 in 2023Kamada Ltd.: 3rd of 6 in 2024Kamada Ltd.: 3rd of 6 in 2025Kamada Ltd.Aquestive Therapeutics, Inc.: 3rd of 3 in 2017Aquestive Therapeutics, Inc.: 3rd of 3 in 2018Aquestive Therapeutics, Inc.: 3rd of 4 in 2019Aquestive Therapeutics, Inc.: 4th of 5 in 2020Aquestive Therapeutics, Inc.: 4th of 5 in 2021Aquestive Therapeutics, Inc.: 4th of 5 in 2022Aquestive Therapeutics, Inc.: 4th of 5 in 2023Aquestive Therapeutics, Inc.: 5th of 6 in 2024Aquestive Therapeutics, Inc.: 5th of 6 in 2025Aquestive Therapeutics, InEvolus, Inc.: 4th of 4 in 2019Evolus, Inc.: 3rd of 5 in 2020Evolus, Inc.: 3rd of 5 in 2021Evolus, Inc.: 2nd of 5 in 2022Evolus, Inc.: 2nd of 5 in 2023Evolus, Inc.: 2nd of 6 in 2024Evolus, Inc.: 1st of 6 in 2025Evolus, Inc.Alpha Teknova, Inc.: 5th of 5 in 2020Alpha Teknova, Inc.: 5th of 5 in 2021Alpha Teknova, Inc.: 5th of 5 in 2022Alpha Teknova, Inc.: 5th of 5 in 2023Alpha Teknova, Inc.: 6th of 6 in 2024Alpha Teknova, Inc.: 6th of 6 in 2025Alpha Teknova, Inc.Ironwood Pharmaceuticals, Inc.: 1st of 2 in 2015Ironwood Pharmaceuticals, Inc.: 1st of 2 in 2016Ironwood Pharmaceuticals, Inc.: 1st of 3 in 2017Ironwood Pharmaceuticals, Inc.: 1st of 3 in 2018Ironwood Pharmaceuticals, Inc.: 1st of 4 in 2019Ironwood Pharmaceuticals, Inc.: 1st of 5 in 2020Ironwood Pharmaceuticals, Inc.: 1st of 5 in 2021Ironwood Pharmaceuticals, Inc.: 1st of 5 in 2022Ironwood Pharmaceuticals, Inc.: 1st of 5 in 2023Ironwood Pharmaceuticals, Inc.: 1st of 6 in 2024Ironwood Pharmaceuticals, Inc.: 2nd of 6 in 2025Ironwood Pharmaceuticals, Pharmanutra S.p.A.: 4th of 6 in 2024Pharmanutra S.p.A.: 4th of 6 in 2025Pharmanutra S.p.A.
Revenue by fiscal year with each company's rank in the group and the source of each figure
Fiscal yearDeva Holding A.S.Kamada Ltd.EIS Eczacibasi Ilaç, Sinai Ve Finansal Yatirimlar Sanayi Ve Ticaret A.S.Aquestive Therapeutics, Inc.Evolus, Inc.Alpha Teknova, Inc.Ironwood Pharmaceuticals, Inc.Pharmanutra S.p.A.
2025—$180 MSEC3rd—$45 MSEC5th$297 MSEC1st$41 MSEC6th$296 MSEC2nd$148 MESEF4th
2024—$161 MSEC3rd—$58 MSEC5th$266 MSEC2nd$38 MSEC6th$351 MSEC1st$125 MESEF4th
2023—$143 MSEC3rd—$51 MSEC4th$202 MSEC2nd$37 MSEC5th$443 MSEC1st—
2022—$129 MSEC3rd—$48 MSEC4th$149 MSEC2nd$41 MSEC5th$411 MSEC1st—
2021—$104 MSEC2nd—$51 MSEC4th$100 MSEC3rd$37 MSEC5th$414 MSEC1st—
2020—$133 MSEC2nd—$46 MSEC4th$57 MSEC3rd$31 MSEC5th$390 MSEC1st—
2019—$127 MSEC2nd—$53 MSEC3rd$35 MSEC4th—$428 MSEC1st—
2018—$114 MSEC2nd—$67 MSEC3rd——$347 MSEC1st—
2017—$103 MSEC2nd—$67 MSEC3rd——$298 MSEC1st—
2016—$77 MSEC2nd————$274 MSEC1st—
2015—$70 MSEC2nd————$150 MSEC1st—
2014——————$76 MSEC—

Sources: SEC = SEC annual reports (10-K, 20-F, 40-F); ESEF = ESEF annual reports (European and UK listed companies); Ed. = The company's annual report, entered by value.today editors; WD = Wikidata, citing the annual report; Cap = value.today market caps (the last of each calendar year). The small ordinal is the rank in the group that year. Hover a figure for its fiscal year end.

Suggested peers of Deva Holding A.S.#

Companies of the same industry, within a hundred times its size (market cap), scored out of 100 for industry, size, country and figures on file. How peers are suggested.

  • Kamada Ltd.KMDA · 🇮🇱 Israel
    Same industry: Pharmaceutical · Similar size: $463 M market cap against $526 M · Same region: Western Asia · Ratios of the last two fiscal years on file
    Market cap $463 M (Aug 1, 2026) · revenue $180 M (year to December 2025)
    91 of 100 (industry or sector 50 + size 29 + country 7 + figures on file 5)
    In the group
  • EIS Eczacibasi Ilaç, Sinai Ve Finansal Yatirimlar Sanayi Ve Ticaret A.S.ECILC.IS · 🇹🇷 Turkey
    Same industry: Pharmaceutical · Similar size: $1.1 B market cap against $526 M · Same country: Turkey
    Market cap $1.1 B (Aug 1, 2026)
    90 of 100 (industry or sector 50 + size 25 + country 15)
    In the group
  • Aquestive Therapeutics, Inc.AQST · 🇺🇸 USA
    Same industry: Pharmaceutical · Similar size: $508 M market cap against $526 M · Ratios of the last two fiscal years on file
    Market cap $508 M (Oct 30, 2026) · revenue $45 M (year to December 2025)
    85 of 100 (industry or sector 50 + size 30 + figures on file 5)
    In the group
  • Evolus, Inc.EOLS · 🇺🇸 USA
    Same industry: Pharmaceutical · Similar size: $501 M market cap against $526 M · Ratios of the last two fiscal years on file
    Market cap $501 M (Oct 16, 2026) · revenue $297 M (year to December 2025)
    85 of 100 (industry or sector 50 + size 30 + figures on file 5)
    In the group
  • Alpha Teknova, Inc.TKNO · 🇺🇸 USA
    Same industry: Pharmaceutical · Similar size: $494 M market cap against $526 M · Ratios of the last two fiscal years on file
    Market cap $494 M (Oct 29, 2026) · revenue $41 M (year to December 2025)
    85 of 100 (industry or sector 50 + size 30 + figures on file 5)
    In the group
  • Ironwood Pharmaceuticals, Inc.IRWD · 🇺🇸 USA
    Same industry: Pharmaceutical · Similar size: $599 M market cap against $526 M · Ratios of the last two fiscal years on file
    Market cap $599 M (Oct 30, 2026) · revenue $296 M (year to December 2025)
    84 of 100 (industry or sector 50 + size 29 + figures on file 5)
    In the group
  • Pharmanutra S.p.A.PHN.MI · 🇮🇹 Italy
    Same industry: Pharmaceutical · Similar size: $593 M market cap against $526 M · Ratios of the last two fiscal years on file
    Market cap $593 M (last known, Jan 5, 2024) · revenue $148 M (year to December 2025)
    84 of 100 (industry or sector 50 + size 29 + figures on file 5)
    In the group
  • Evotec SEEVT.DE · 🇩🇪 Germany
    Same industry: Pharmaceutical · Similar size: $720 M market cap against $526 M · Ratios of the last two fiscal years on file
    Market cap $720 M (Aug 1, 2026) · revenue $862 M (year to December 2024)
    83 of 100 (industry or sector 50 + size 28 + figures on file 5)
    + Add
  • Collegium Pharmaceutical, Inc.COLL · 🇺🇸 USA
    Same industry: Pharmaceutical · Similar size: $715 M market cap against $526 M · Ratios of the last two fiscal years on file
    Market cap $715 M (Oct 28, 2026) · revenue $781 M (year to December 2025)
    83 of 100 (industry or sector 50 + size 28 + figures on file 5)
    + Add
  • Solid Biosciences Inc.SLDB · 🇺🇸 USA
    Same industry: Pharmaceutical · Similar size: $713 M market cap against $526 M · Ratios of the last two fiscal years on file
    Market cap $713 M (Oct 30, 2026)
    83 of 100 (industry or sector 50 + size 28 + figures on file 5)
    + Add
  • Saudi Pharmaceutical Industries and Medical Appliances Corporation2070.SR · 🇸🇦 Saudi Arabia
    Same industry: Pharmaceutical · Similar size: $995 M market cap against $526 M · Same region: Western Asia
    Market cap $995 M (Aug 1, 2026) · revenue $389 M (year to December 2021)
    83 of 100 (industry or sector 50 + size 26 + country 7)
    + Add
  • Aker BioMarine ASAKBM.OL · 🇳🇴 Norway
    Same industry: Pharmaceutical · Similar size: $382 M market cap against $526 M · Ratios of the last two fiscal years on file
    Market cap $382 M (last known, Jan 5, 2024) · revenue $218 M (year to December 2025)
    83 of 100 (industry or sector 50 + size 28 + figures on file 5)
    + Add

Any figure over the years, other peers or a saved group: open this group in the peer workspace.